Enlivex Therapeutics Ltd. has begun a voluntary delisting of its ordinary shares from the Tel Aviv Stock Exchange (TASE). The last day of trading on TASE will be April 23, 2026, with removal from the exchange around April 26, 2026. The company will remain listed on Nasdaq’s Capital Market under ticker ENLV.
The move is intended to reduce duplicative administrative costs and streamline regulatory compliance. By consolidating its public listing to a single U.S. exchange, Enlivex expects to lower the cost of maintaining dual reporting requirements and to focus investor relations on the larger U.S. capital market.
Enlivex’s dual‑platform strategy—its Allocetra cell‑therapy pipeline for osteoarthritis and its RAIN prediction‑markets token used as a digital‑asset treasury—has driven the decision. The company completed a $212 million private placement in November 2025 to fund the RAIN treasury, and the token was listed on KuCoin on January 6, 2026. The delisting allows Enlivex to align its reporting obligations with U.S. securities regulations while maintaining the flexibility of its crypto‑treasury.
The company’s Allocetra™ pipeline continues to advance. Positive six‑month topline data for knee osteoarthritis were reported in November 2025, and a Phase IIb trial is scheduled for Q2 2026. The delisting does not affect the clinical development timeline but signals Enlivex’s intent to prioritize U.S. market engagement for its biotech and digital‑asset initiatives.
By removing the TASE listing, Enlivex aims to enhance liquidity for shareholders. Consolidation to Nasdaq is expected to reduce the number of trading venues, potentially improving price discovery and reducing transaction costs for investors who currently trade on both exchanges.
The company’s management emphasized that the delisting will not alter its strategic focus on advancing Allocetra and expanding the RAIN treasury. The decision reflects a broader trend among Israeli companies to consolidate listings in the U.S. to benefit from larger investor bases and streamlined compliance.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.